President and Chief Executive Officer
Paul Lévesque was hired as President and CEO in March 2020. He came to Theratechnologies with 35 years’ experience in the research-based pharmaceutical industry including 28 years spent at Pfizer Inc.
Prior to joining Theratechnologies, Paul spent half of his professional career outside of Canada to take on various marketing and general management roles in Europe, Asia and the United States. His last assignment at Pfizer was to lead the Global Rare Disease Business Unit based in New York City. Along with the Head of Research and Development, he was responsible to drive the commercial success and the pipeline of the Unit.
Paul holds a BSc in biochemistry from Laval University and a Diploma in Management from McGill University.